Christian Albrechts University Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2004
NCT00204568
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Christian-Albrechts University Kiel, Germany | Institute for Clinical Molecular Biology, Christian-Albrechts-University, Kiel | University Medical Center , Comprehensive Cancer Center North, Christian-Albrechts-University

Active Ingredients

Drugs in Phase 2 Trials (2)

cyclophosphamide (cytoxan) (1 trial)

doxorubicin (Doxil) (1 trial)

Drugs in Other Trials (2)

carbamazepine (tegretol) (1 trial)

lacosamide (vimpat) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Sarcoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 4